<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">In silico inhibition study of phytocompounds derived from Bryophyllum pinnatum, Cassia sieberiana, Cassia tora and Tamarindus indica against breast cancer proteins</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2024-06-07">07 June 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Gadanya</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Chemistry</orgName>
								<orgName type="institution">Sa&apos;adatu Rimi University of Education</orgName>
								<address>
									<settlement>Kano</settlement>
									<country key="NG">Nigeria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Nuhu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Chemistry</orgName>
								<orgName type="institution">Sa&apos;adatu Rimi University of Education</orgName>
								<address>
									<settlement>Kano</settlement>
									<country key="NG">Nigeria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Muhammad</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Biochemistry</orgName>
								<orgName type="institution">Kano University of Science and Technology</orgName>
								<address>
									<settlement>Wudil, Kano</settlement>
									<country key="NG">Nigeria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><forename type="middle">Y</forename><surname>Habib</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Chemistry</orgName>
								<orgName type="institution">Sa&apos;adatu Rimi University of Education</orgName>
								<address>
									<settlement>Kano</settlement>
									<country key="NG">Nigeria</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">In silico inhibition study of phytocompounds derived from Bryophyllum pinnatum, Cassia sieberiana, Cassia tora and Tamarindus indica against breast cancer proteins</title>
					</analytic>
					<monogr>
						<idno type="ISSN">2221-1063 (Print), 2222-503X</idno>
						<imprint>
							<date type="published" when="2024-06-07">07 June 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">6AFC73FE8D0AC2DA2A5FCDCC905B4476</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2025-05-12T17:53+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>In silico study</term>
					<term>Medicinal plants</term>
					<term>Breast cancer</term>
					<term>HER2</term>
					<term>3pp0</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Breast cancer is a type of cancer that originates in the cells of the breast tissues. B. pinnatum, C. sieberiana, C. tora and T. indica are the four medicinal plants whose phytochemicals were used for this In silico study. In this study, eight different ligands were evaluated for their interactions with the human epidermal growth factor 2 (HER2) protein (PDB ID: 3pp0). The ligands, including Apigenin, Bryophyllin A, Catechin, Emodin, Islandicin, Quercetin, Sitosterol, and Taxifolin, were assessed based on binding scores and hydrogen bond interactions. Among these ligands, Apigenin exhibited the highest binding score (-6.5 kcal/mol), indicating its strong binding affinity to the HER2 protein. Bryophyllin A also displayed a significant binding score (-6.3 kcal/mol) and formed a hydrogen bond with Met 901. Catechin, while having a slightly lower binding score (-5.9 kcal/mol), engaged in hydrogen bonds with Ser 728, Arg 849, and Asn 850. Emodin, Quercetin, and Taxifolin demonstrated moderate binding scores (-6.2, -6.4, and -6.0 kcal/mol, respectively) and formed hydrogen bonds with Asp 863 and Met 801. Islandicin formed a hydrogen bond with Gly 787 and Leu 786, with a binding score of -6.1 kcal/mol. Sitosterol exhibited the lowest binding score (-5.3 kcal/mol) but still established a hydrogen bond with Asp 863 and Met 801. Overall, Apigenin and Bryophyllin A emerged as the most promising ligands due to their strong binding affinities and specific hydrogen bond interactions with HER2. However, experimental validation is essential to confirm these findings and explore their potential as inhibitors or modulators of HER2. Furthermore, all ligands were successfully docked to the active sites of the HER2 protein, indicating their potential relevance in targeting HER2-related pathways. Importantly, the ligands exhibited favorable pharmacokinetic properties with no violations, except for Sitosterol, which showed minor violations in Lipinski, Ghose, Egan, and Muegge's rules.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Breast cancer is a type of cancer that originates in the cells of the breast tissues. It primarily affects women but can also occur in men. It is characterized by the uncontrolled growth of abnormal cells in the breast tissue, forming a lump or mass called a tumor <ref type="bibr" target="#b3">(Dashti et al., 2020)</ref>. Breast cancer can spread to other parts of the body through the lymphatic system or bloodstream, leading to metastasis <ref type="bibr" target="#b6">(Iqbal and Iqbal, 2014;</ref><ref type="bibr" target="#b16">Pegram and Jackisch, 2023)</ref>. Early detection and advancements in treatment have significantly improved the prognosis and survival rates for those diagnosed with breast cancer <ref type="bibr" target="#b16">(Pegram and Jackisch, 2023)</ref>. The exact causes of breast cancer are not fully understood, but several risk factors have been identified. These include genetics (family history of breast cancer or carrying certain mutations like BRCA1 and BRCA2), hormonal factors (early onset of menstruation, late menopause, hormone replacement therapy), age (risk increases with age), certain inherited gene mutations, exposure to ionizing radiation, obesity, alcohol consumption, and more <ref type="bibr" target="#b20">(Sun et al., 2017)</ref>. While these factors can increase the risk, not everyone with these risk factors will develop breast cancer. Breast cancer can have wide-ranging effects on individuals physically, emotionally, and socially. Physically, it can lead to symptoms such as a lump in the breast, changes in breast size or shape, skin changes, and nipple discharge <ref type="bibr" target="#b8">(Kim, 2021;</ref><ref type="bibr" target="#b20">Sun et al., 2017)</ref>. Emotionally, the diagnosis can cause anxiety, fear, depression, and uncertainty. Socially, it may impact relationships and daily life. The effects of treatment, including surgery, chemotherapy, radiation, and hormone therapy, can also cause physical and emotional challenges. Treatment for breast cancer depends on the stage and type of cancer, as well as individual factors <ref type="bibr" target="#b6">(Iqbal and Iqbal, 2014;</ref><ref type="bibr" target="#b16">Pegram and Jackisch, 2023)</ref>. Common treatments include surgery (lumpectomy or mastectomy), radiation therapy, chemotherapy, targeted therapy, hormone therapy, and immunotherapy <ref type="bibr" target="#b2">(Burguin and Diorio, 2021;</ref><ref type="bibr">Moo et al., 2019)</ref>. Treatment plans may involve a combination of these approaches <ref type="bibr" target="#b16">(Pegram and Jackisch, 2023)</ref>. The goal is to remove or destroy the cancer cells, prevent recurrence, and improve overall quality of life <ref type="bibr">(Moo et al., 2019)</ref>. Researchers have identified specific molecular and genetic targets that play a role in the development and growth of breast cancer. Targeted therapies focus on these specific molecules, receptors, and genetic mutations to inhibit cancer growth <ref type="bibr" target="#b2">(Burguin and Diorio, 2021)</ref>. Some targeted therapies are designed to block hormone receptors (such as estrogen or progesterone receptors), while others target overexpressed proteins like HER2. HER2, or human epidermal growth factor receptor 2, is a protein that plays a role in regulating cell growth and division. In some breast cancers, there is an overexpression or amplification of the HER2 gene, leading to an increased production of the HER2 protein <ref type="bibr" target="#b5">(Hussain et al., 2020;</ref><ref type="bibr" target="#b6">Iqbal and Iqbal, 2014)</ref>. HER2-positive breast cancer is an important target in breast cancer treatment because the overexpression of HER2 is associated with more aggressive tumor growth and a poorer prognosis <ref type="bibr" target="#b6">(Iqbal and Iqbal, 2014)</ref>. Targeting HER2 can help slow down the progression of the cancer and improve treatment outcomes. In molecular docking studies, the HER2 (human epidermal growth factor receptor 2) protein is commonly used as a target protein, especially when investigating the binding of potential drug compounds or ligands <ref type="bibr" target="#b6">(Iqbal and Iqbal, 2014;</ref><ref type="bibr" target="#b16">Pegram and Jackisch, 2023;</ref><ref type="bibr">Sohrab, 2022)</ref>. HER2 is a protein that plays a role in regulating cell growth and division <ref type="bibr" target="#b6">(Iqbal and Iqbal, 2014)</ref>. In some breast cancers, there is an overexpression or amplification of the HER2 gene, leading to an increased production of the HER2 protein <ref type="bibr" target="#b6">(Iqbal and Iqbal, 2014</ref> Indica (TI) <ref type="bibr" target="#b1">(Archer et al., 2019;</ref><ref type="bibr" target="#b9">Meena and Niranjan, 2010;</ref><ref type="bibr" target="#b15">Pawar et al., 2011;</ref><ref type="bibr" target="#b18">Sarwa et al., 2014;</ref><ref type="bibr">Sookying and Duangjai, n.d.)</ref> (Fig. <ref type="figure">1</ref>). These plants demonstrated plausible properties such as phytochemical, ethnobotanical, pharmacological and biological properties <ref type="bibr" target="#b1">(Archer et al., 2019;</ref><ref type="bibr" target="#b4">Faboro et al., 2016;</ref><ref type="bibr" target="#b7">Khan and Odokpe, 2020;</ref><ref type="bibr" target="#b9">Meena and Niranjan, 2010;</ref><ref type="bibr">Ms and Ali, 2018;</ref><ref type="bibr" target="#b17">Salami et al., 2013;</ref><ref type="bibr" target="#b18">Sarwa et al., 2014;</ref><ref type="bibr">Sookying and Duangjai, n.d.)</ref>. This study utilizes the potentials of BP, CB, CT and TI in the inhibition study of one of the breast cancer target proteins, HER2 through Insilco studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fig. 1. Selected medicinal plants</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ligand preparation</head><p>Hundreds of phytochemicals obtained from BP, CB, CT and TI plants were reported from literatures and were used in the study. The ligand preparation procedure followed a similar procedure reported from our previously reported literature <ref type="bibr" target="#b12">(Muhammad et al., 2023)</ref>. Three-dimensional structures of the identified plants' phytochemicals were retrieved from the PubChem database (www.pubchem.ncbi.nlm.nih.gov) in SDF format, Minimized and converted to PDBQT with Pyrex-Open Babel software.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Protein target preparation</head><p>The protein preparation procedure also followed a similar procedure reported from our previously reported literature <ref type="bibr">(Muhammad et al., 2022)</ref>. The PDB structure of human epidermal growth factor protein 2 (HER2) was retrieved from the Protein Data Bank (https://www.rcsb.org) (PDB ID: 3PP0). All hetero atoms were removed from the protein molecule using UCF Chimera (Version 1. 12).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular docking</head><p>Structural-based virtual screening was employed to find the potential inhibitors of HER2 (3pp0) protein <ref type="bibr">(Herrera-calderon et al., 2020)</ref>. The docking and scoring functions were validated before the docking was carried out. Phytochemicals that interacted with the 3pp0 catalytic site residues were selected for further studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedure for post docking analysis</head><p>Post molecular docking analysis was carried out by re-docking the suitable models of the ligands that binded to the active site of the 3pp0 protein using UCF Chimera (Version 1. 12) to obtain the proteinligands complex and subsequently the suitable models, which are the compounds that interacted with the 3pp0 key catalytic residues were considered for post docking studies using Discovery Studio (Version 2.0) to study the protein -ligands interactions <ref type="bibr">(Muhammad et al., 2022)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ADMET analysis</head><p>The procedure used here is directly adopted from our previously reported literature <ref type="bibr">(Muhammad et</ref>  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results and Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular docking analysis</head><p>The chemical structures of the selected ligands are shown in Fig. <ref type="figure" target="#fig_1">2</ref>. These ligands are derived from medicinal plants selected for the study. These ligands indeed demonstrate plausible binding affinities to the HER2 protein (Table <ref type="table" target="#tab_1">1</ref>, Fig. <ref type="figure">3</ref>).</p><p>The molecular docking is technically a physical interaction between a ligand and a protein target. In this study, the selected ligands were successfully and efficiently bonded to the active site of the HER2 to form a protein -ligands' complex as shown in Fig. <ref type="figure">3</ref>.</p><p>The following amino acid residues Leu726, Val734, Ala751, Lys753, Thr798, Gly804, Arg849, Leu852, Thr862, and Asp863 were found in common interaction as compared to the standard compound Lapatinib (Sohrab, 2022).</p><p>The results of the molecular docking typically comprise of the binding scores, root mean square deviations (RMSD) and the protein -ligands interactions. Binding scores and the protein -ligands interactions are presented in Table <ref type="table" target="#tab_1">1</ref>. The extent of the interactions that shows the specific bonding between the ligands and the HER2 amino acid residue is also presented in Fig. <ref type="figure">4</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Root mean square deviation (rmsd) analysis</head><p>Root Mean Square Deviation (RMSD) is a measure of the structural similarity or deviation between two molecular structures, typically a reference (in this case, the original ligand conformation in the crystal structure 3pp0) and the docked ligand conformations.     excellent filters for drug-like compound evaluation <ref type="bibr" target="#b13">(Ogidigo et al., 2018)</ref>. Results show that most ligands possess number of rotatable bonds within acceptable range with the exception of Sitosterol, which has a rotatable bond of 6 as revealed in Table <ref type="table" target="#tab_3">3</ref>.</p><p>Drug-likeness and Rule of Five also play an important role in determining compound drug-likeness. The number of rotatable bonds is considered in the rule of five, a guideline used to assess drug-likeness. The rule of five suggests that drug molecules should have no more than five rotatable bonds to ensure optimal oral absorption and bioavailability. Table <ref type="table" target="#tab_4">4</ref> presents  <ref type="table" target="#tab_4">4</ref>.</p><formula xml:id="formula_0">different</formula><p>Similar study was also reported from literature <ref type="bibr" target="#b13">(Ogidigo et al., 2018)</ref>.</p><p>Table <ref type="table" target="#tab_5">5</ref> presents the parameters recorded for the absorption, distribution, metabolism and excretion (ADME) properties of the ligands. Ali solubility refers to the solubility parameter that characterizes the solubility properties of a substance based on its dispersion forces, polar forces, and hydrogen bonding forces. In drug discovery, the solubility of a compound is a critical factor as it directly affects its bioavailability, formulation development, and overall efficacy. Results show that 4 ligands are soluble, 3 moderate, 1poorly soluble and 0 insoluble (Table <ref type="table" target="#tab_5">5</ref>).</p><p>This shows that the general solubility of most of these compounds are remarkable. The blood-brain barrier (BBB) is a highly selective barrier that separates the blood circulation from the brain and central nervous system (CNS). It plays a crucial role in protecting the brain from harmful substances but also poses a challenge in drug discovery and development.</p><p>Results show that 6 ligands show excellent BBB properties while only 2 ligands violate BBB predictions (Table <ref type="table" target="#tab_5">5</ref>).</p><p>Lead-likeness is a concept in drug discovery that refers to the set of properties and characteristics that are commonly associated with successful drug leads. show that values obtained in this study are within the acceptable range (1-10) (Table <ref type="table" target="#tab_5">5</ref>).  <ref type="bibr">et al., 2018)</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>://lmmd.ecust.edu.cn/admetsar2/) servers were utilizing to study the metabolic and toxicological properties of the phytocompounds. The canonical smiles of the phytocompounds were utilized to estimate the corresponding values of the ADMET (absorption, distribution, metabolism, excretion and toxicity)<ref type="bibr" target="#b12">(Muhammad et al., 2023)</ref>.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc>Fig. 2. Chemical structures of the selected ligands</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>Here, we have eight ligands: Apigenin, Bryophyllin A, Catechin, Emodin, Islandicin, Quercetin, Sitosterol, and Taxifolin, and we are comparing their docked conformations against the reference structure of 3pp0. The RMSD values represent the deviation of the ligand's structure after docking from the original crystallographic structure of 3pp0. RMSD values within the lower and upper boundaries indicate that the docked ligand conformations are within an acceptable range of structural similarity to the reference structure (3pp0). Emodin and Islandicin have the lowest upper boundary RMSD values (1.668 and 1.838 Ǻ, respectively), suggesting that their docked conformations closely resemble the reference structure. Quercetin has a low lower boundary RMSD (3.209 Ǻ) and an even lower upper boundary RMSD (1.528 Ǻ), indicating a very close match to the reference structure. Bryophyllin A, Catechin, and Taxifolin also have relatively low RMSD values within the specified boundaries, indicating good docking results. Apigenin and Sitosterol have slightly higher RMSD values, but they still fall within the acceptable range. Overall, these RMSD values suggest that the molecular docking simulations for these ligands against 3pp0 have resulted in conformations that closely resemble the crystallographic structure, with Emodin, Islandicin, and Quercetin showing particularly promising results in terms of structural similarity. However, further validation and analysis, such as considering binding energy and specific interactions, are necessary to draw more definitive conclusions about the binding affinities and biological relevance of these ligand-protein complexes.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc>types of filters used in drug discovery. Some of these filters include Lipinki, Ghose, Veber, Egan and Muegge. These filters are one of the tools used in pharmacokinetics. The Lipinski's Rule of Five, also known as the Rule of Five, is a widely used guideline in drug discovery to assess the drug-likeness and oral bioavailability of organic compounds. The Ghose Rule, also known as the Ghose Filter, is a rule developed to assess the drug-likeness of organic compounds in drug discovery. It is based on a set of physicochemical properties that are important for oral bioavailability. Other rules include Veber, Egan and Muegge and the corresponding data are presented in Table 4. All the ligands show no violations except for Sitosterol which shows few violations corresponding to Lipinski, Ghose, Egan and Muegge, respectively as shown in Table</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc>Among eight different ligands, Apigenin emerged as the most promising candidate, displaying the highest binding score (-6.5) and forming crucial hydrogen bonds with Asp 863 and Met 801. This suggests a robust and specific binding affinity to the HER2 protein. Bryophyllin A also exhibited a strong binding score (-6.3) and formed a significant hydrogen bond with Met 901. This interaction underscores its potential as a HER2 inhibitor. Catechin, despite a slightly lower binding score (-5.9), demonstrated meaningful interactions by forming hydrogen bonds with Ser 728, Arg 849, and Asn 850. Emodin, Quercetin, and Taxifolin, with moderate binding scores (-6.2, -6.4, and -6.0, respectively), all interacted via hydrogen bonds with Asp 863 and Met 801. These ligands may warrant further exploration. Islandicin formed a hydrogen bond with Gly 787 and Leu 786, complementing its binding score of -6.1. Sitosterol, with the lowest binding score (-5.3), still displayed a binding interaction through hydrogen bonds with Asp 863 and Met 801. Overall, Apigenin and Bryophyllin A exhibit the most promising binding affinities and hydrogen bond interactions with HER2, making them strong candidates for further investigation as potential HER2 inhibitors or modulators. In conclusion, this molecular docking study provides valuable insights into potential ligands for HER2 targeting. Further research and experimentation are warranted to validate these findings.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc>Binding scores and 3PP0 residues' interactions with the ligands</figDesc><table><row><cell cols="3">Compound name PubChem CID Binding score</cell><cell>Hydrogen bond</cell><cell>Other interactions</cell></row><row><cell></cell><cell></cell><cell>(kcal/mol)</cell><cell>interaction</cell><cell></cell></row><row><cell>Apigenin</cell><cell>10151</cell><cell>-6.5</cell><cell cols="2">Asp 863, Met 801 Ala 751, Glu 770, Met 774, Phe 864, Thr</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>852, Thr 798, Val 734, Lys 753, Asn 850,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Leu 726, Leu 796, Leu 852, Gln 799</cell></row><row><cell>Bryophyllin A</cell><cell>222284</cell><cell>-6.3</cell><cell cols="2">Asp 863, Met 901 Glu 770, Met 774, Phe 864, Thr 852, Val</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>734, Lys 753, Asn 850, Leu 726, Leu 726,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Leu , Leu 796, Leu 852, Gln 799</cell></row><row><cell>Catechin</cell><cell>3220</cell><cell>-5.9</cell><cell>Ser 728, Arg 849, Asn</cell><cell>Ala 730, Arg 756, Asp 845, Gly 729, Lys</cell></row><row><cell></cell><cell></cell><cell></cell><cell>850</cell><cell>798, Phe 731</cell></row><row><cell>Emodin</cell><cell>439533</cell><cell>-6.2</cell><cell cols="2">Asp 863, Met 801 Glu 770, Lys 753, Asn 850, Leu 726, Leu</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>785, Gln 799</cell></row><row><cell>Islandicin</cell><cell>5280343</cell><cell>-6.1</cell><cell>Gly 787, Leu 786</cell><cell>Leu 715, Leu 726, Leu 796, Ile 752, Thr</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>798, Val 750</cell></row><row><cell>Quercetin</cell><cell>5280794</cell><cell>-6.4</cell><cell cols="2">Asp 863, Met 801 Glu 770, Met 774, Phe 864, Thr 798, Thr</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>862, Val 734, Lys 753, Asn 850, Leu 785,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Leu 726, Leu 795, Leu 852, Gln 799,</cell></row><row><cell>Sitosterol</cell><cell>5280863</cell><cell>-5.3</cell><cell cols="2">Asp 863, Met 801 Ala 751, Glu 770, Met 714, Phe 864, Thr</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>862, Val 734, Lys 753, Asn 850, Leu 785,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Leu 726, Leu 796, Leu 852, Gln 799</cell></row><row><cell>Taxifolin</cell><cell>9064</cell><cell>-6.0</cell><cell cols="2">Asp 863, Met 801 Ala 751, Glu 770, Met 774, Phe 864, Val</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>734, Lys 753, Asn 850, Leu 852, Leu 726,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Gln 799</cell></row><row><cell cols="4">Table 2 presents the RMSD values of the ligands.</cell><cell></cell></row></table><note>Lower RMSD values indicate a closer structural match between the predicted and reference structures, suggesting a more accurate docking result.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc>RMSD analysis data</figDesc><table><row><cell>Compound</cell><cell>RMSD (Ǻ)</cell><cell>RMSD (Ǻ)</cell></row><row><cell>name</cell><cell>(Upper boundary)</cell><cell>(Lower boundary)</cell></row><row><cell>Apigenin</cell><cell>5.091</cell><cell>2.553</cell></row><row><cell>Bryophyllin A</cell><cell>4.822</cell><cell>3.304</cell></row><row><cell>Catechin</cell><cell>5.804</cell><cell>3.468</cell></row><row><cell>Emodin</cell><cell>6.828</cell><cell>1.668</cell></row><row><cell>Islandicin</cell><cell>6.841</cell><cell>1.838</cell></row><row><cell>Quercetin</cell><cell>3.209</cell><cell>1.528</cell></row><row><cell>Sitosterol</cell><cell>5.874</cell><cell>4.293</cell></row><row><cell>Taxifolin</cell><cell>5.472</cell><cell>3.220</cell></row><row><cell cols="3">Drug-likeness properties and ADMET screening</cell></row><row><cell cols="3">The drug-likeness properties entails the intrinsic</cell></row><row><cell cols="3">properties demonstrated by the ligands after</cell></row><row><cell cols="3">molecular docking and ADMET screening. This</cell></row><row><cell cols="3">property entails the relationship between a chemical</cell></row><row><cell cols="3">structure, composition, size and bonding chemistry</cell></row></table><note>between a ligand and the HER2 protein. The pharmacokinetics of BP, CS, CT and TI have been successfully carried out and the results were presented across Table3-4.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc>Structural properties of ligands</figDesc><table><row><cell>Ligand</cell><cell>Molecular</cell><cell cols="2">MW (g/mol) Heavy</cell><cell>Aromatic</cell><cell>Rotatable</cell><cell>H-Bond</cell><cell>H-Bond</cell></row><row><cell></cell><cell>formulae</cell><cell></cell><cell>atoms</cell><cell></cell><cell>bonds</cell><cell>acceptors</cell><cell>donors</cell></row><row><cell>Apigenin</cell><cell>C15H10O5</cell><cell>270.24</cell><cell>20</cell><cell>16</cell><cell>1</cell><cell>5</cell><cell>3</cell></row><row><cell>Bryophyllin A</cell><cell>C26H32O8</cell><cell>472.53</cell><cell>34</cell><cell>6</cell><cell>2</cell><cell>8</cell><cell>2</cell></row><row><cell>Catechin</cell><cell>C15H14O6</cell><cell>290.27</cell><cell>21</cell><cell>12</cell><cell>1</cell><cell>6</cell><cell>5</cell></row><row><cell>Emodin</cell><cell>C15H10O4</cell><cell>254.24</cell><cell>19</cell><cell>12</cell><cell>0</cell><cell>4</cell><cell>2</cell></row><row><cell>Islandicin</cell><cell>C15H10O4</cell><cell>254.24</cell><cell>19</cell><cell>12</cell><cell>0</cell><cell>4</cell><cell>2</cell></row><row><cell>Quercetin</cell><cell>C15H10O7</cell><cell>302.24</cell><cell>22</cell><cell>16</cell><cell>1</cell><cell>7</cell><cell>5</cell></row><row><cell>Sitosterol</cell><cell>C29H50O</cell><cell>414.71</cell><cell>30</cell><cell>0</cell><cell>6</cell><cell>1</cell><cell>1</cell></row><row><cell>Taxifolin</cell><cell>C15H12O7</cell><cell>304.25</cell><cell>22</cell><cell>12</cell><cell>1</cell><cell>7</cell><cell>5</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 .</head><label>4</label><figDesc>Rules violations</figDesc><table><row><cell>Compound</cell><cell>Lipinski</cell><cell>Ghose</cell><cell>Veber</cell><cell>Egan</cell><cell>Muegge</cell></row><row><cell></cell><cell>#violations</cell><cell>#violations</cell><cell>#violations</cell><cell>#violations</cell><cell>#violations</cell></row><row><cell>Apigenin</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Bryophyllin A</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Catechin</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Emodin</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Islandicin</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Quercetin</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Sitosterol</cell><cell>1</cell><cell>3</cell><cell>0</cell><cell>1</cell><cell>2</cell></row><row><cell>Taxifolin</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc>ADME properties</figDesc><table><row><cell>Ligand</cell><cell>GI</cell><cell>BBB</cell><cell>Pgp</cell><cell cols="2">Bioavailability</cell><cell>Lead-likeness</cell><cell>Ali solubility</cell><cell>Synthetic</cell></row><row><cell></cell><cell>absorption</cell><cell>permeant</cell><cell>substrate</cell><cell>score</cell><cell></cell><cell>#violations</cell><cell></cell><cell>accessibility</cell></row><row><cell>Apigenin</cell><cell>High</cell><cell>No</cell><cell>No</cell><cell>0.17</cell><cell></cell><cell>0</cell><cell>Moderately soluble</cell><cell>2.96</cell></row><row><cell>Bryophyllin A</cell><cell>High</cell><cell>No</cell><cell>Yes</cell><cell>0.55</cell><cell></cell><cell>1</cell><cell>Soluble</cell><cell>7.33</cell></row><row><cell>Catechin</cell><cell>High</cell><cell>No</cell><cell>Yes</cell><cell>0.55</cell><cell></cell><cell>0</cell><cell>Soluble</cell><cell>3.5</cell></row><row><cell>Emodin</cell><cell>High</cell><cell>Yes</cell><cell>No</cell><cell>0.55</cell><cell></cell><cell>1</cell><cell>Moderately soluble</cell><cell>2.47</cell></row><row><cell>Islandicin</cell><cell>High</cell><cell>Yes</cell><cell>No</cell><cell>0.55</cell><cell></cell><cell>1</cell><cell>Moderately soluble</cell><cell>2.47</cell></row><row><cell>Quercetin</cell><cell>High</cell><cell>No</cell><cell>No</cell><cell>0.55</cell><cell></cell><cell>0</cell><cell>Soluble</cell><cell>3.23</cell></row><row><cell>Sitosterol</cell><cell>Low</cell><cell>No</cell><cell>No</cell><cell>0.55</cell><cell></cell><cell>2</cell><cell>Poorly soluble</cell><cell>6.3</cell></row><row><cell>Taxifolin</cell><cell>High</cell><cell>No</cell><cell>No</cell><cell>0.55</cell><cell></cell><cell>0</cell><cell>Soluble</cell><cell>3.51</cell></row><row><cell cols="5">Structural properties such as number of heavy atoms,</cell><cell cols="4">g/mol. Table 3 presents different molecular weights</cell></row><row><cell cols="5">rotatable bonds, hydrogen donors and acceptors were</cell><cell cols="4">prediction scores of compounds under study. A total</cell></row><row><cell cols="5">all predicted. Parameters such as molecular weights,</cell><cell cols="4">of zero compound have molecular weight less than</cell></row><row><cell cols="5">heavy atoms, number of aromatic rings, rotatable</cell><cell cols="4">500 g/mol. This shows remarkable drug like</cell></row><row><cell cols="5">bonds, hydrogen bond donors and hydrogen bond</cell><cell cols="4">properties of all the ligands. All ligands have</cell></row><row><cell cols="5">acceptors are tools used in filtering the most effective</cell><cell cols="4">hydrogen bond donor below 5 while 4 ligands have</cell></row><row><cell cols="5">drug-like compounds and the data are presented in</cell><cell cols="4">hydrogen bond acceptors above 5. Aromatic rings</cell></row><row><cell cols="5">Table 3. The presence of heavy atoms in drug</cell><cell cols="4">play a crucial role in drug discovery due to their</cell></row><row><cell cols="5">molecules can have various effects on drug discovery,</cell><cell cols="4">unique chemical properties and interactions with</cell></row><row><cell cols="5">including influencing drug-target interactions,</cell><cell cols="4">biological targets. Aromatic rings also enhance</cell></row><row><cell cols="5">pharmacokinetics, and physicochemical properties.</cell><cell cols="4">binding interactions, target specificity, lipophilicity</cell></row><row><cell cols="5">Key effects of heavy atoms in drug discovery include;</cell><cell cols="4">and metabolic stability. Predicted number of aromatic</cell></row><row><cell>increased</cell><cell>molecular</cell><cell>weight,</cell><cell cols="2">hydrophobic</cell><cell cols="4">rings in each compound are presented in Table 3.</cell></row><row><cell cols="5">interactions, electronic effects, metabolism and</cell><cell cols="4">Results show that most compounds show satisfactory</cell></row><row><cell cols="5">clearance, radiolabeling and imaging. Molecular</cell><cell cols="4">amount of aromatic rings. The number of rotatable</cell></row><row><cell cols="5">weights of compounds that are supposed to be drug-</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">like are characterized by having small molecular</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">weights. Large molecular weights compounds are</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">characterized by having molecular weights above 500</cell><cell></cell><cell></cell><cell></cell></row></table><note>bonds in a drug molecule is an important factor in drug discovery and design. Number of rotatable bonds between 1 and 2 are reported from literature as</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 6 .</head><label>6</label><figDesc>Toxicological properties</figDesc><table><row><cell cols="2">Compounds</cell><cell cols="2">Carcinogenicity</cell><cell cols="2">Acute oral toxicity</cell><cell>Plasma protein binding</cell><cell>Water solubility</cell></row><row><cell>Apigenin</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>III</cell><cell>1.08</cell><cell>-2.78</cell></row><row><cell cols="2">Bryophyllin A</cell><cell>NA</cell><cell></cell><cell></cell><cell>I</cell><cell>1.07</cell><cell>-4.309</cell></row><row><cell>Catechin</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>IV</cell><cell>1.01</cell><cell>-3.10</cell></row><row><cell>Emodin</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>III</cell><cell>1.08</cell><cell>-3.02</cell></row><row><cell>Islandicin</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>III</cell><cell>1.07</cell><cell>-3.20</cell></row><row><cell>Quercetin</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>II</cell><cell>1.16</cell><cell>-2.99</cell></row><row><cell>Sitosterol</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>III</cell><cell>1.25</cell><cell>-4.13</cell></row><row><cell>Taxifolin</cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell>II</cell><cell>1.02</cell><cell>-2.99</cell></row><row><cell cols="6">The evaluation of carcinogenicity is an essential</cell><cell>but is considered unsafe for human use due to</cell></row><row><cell cols="6">aspect of the safety assessment of potential drug</cell><cell>reproductive effect as a result of low toxicity profile</cell></row><row><cell cols="6">candidates. Carcinogenicity refers to the ability of a</cell><cell>(Rahman et al., 2022) . However, Bryophyllum B was</cell></row><row><cell cols="6">substance to induce cancer. During drug</cell><cell>predicted to act as a potential therapy for</cell></row><row><cell cols="6">development, extensive studies are conducted to</cell><cell>atherosclerosis disease (Yuniwati, 2022). Other</cell></row><row><cell cols="6">assess the potential carcinogenic effects of</cell><cell>reported compounds of BP that demonstrate</cell></row><row><cell cols="6">compounds. These studies typically involve in vitro</cell><cell>remarkable pharmacokinetic profiles include;</cell></row><row><cell cols="6">tests, animal studies, and epidemiological data</cell><cell>kaemferol, acaecetin, luteolin and patuletin (Ogidigo</cell></row><row><cell cols="6">analysis. In this study, all the ligands show absence of</cell></row><row><cell cols="6">carcinogenicity (Table 6). Acute oral toxicity is a</cell></row><row><cell cols="6">crucial consideration in drug discovery as it assesses</cell></row><row><cell cols="6">the potential adverse effects of a compound when</cell></row><row><cell cols="6">ingested orally. It provides important information</cell></row><row><cell cols="6">about the safety profile of a drug candidate and helps</cell></row><row><cell>guide</cell><cell cols="2">decision-making</cell><cell>during</cell><cell></cell><cell>preclinical</cell></row><row><cell cols="6">development. Oral acute toxicity is classified into</cell></row><row><cell cols="6">high, moderate, slight and non-toxic. 1 ligand show</cell></row><row><cell cols="6">high, 2 moderate, 4 are slightly toxic while 1 is non-</cell></row><row><cell cols="6">toxic (Table 6). The water solubility of a drug is a</cell></row><row><cell cols="6">critical parameter in drug discovery and</cell></row><row><cell cols="6">development, as it can significantly impact the drug's</cell></row><row><cell cols="2">pharmacokinetics,</cell><cell cols="2">formulation,</cell><cell>and</cell><cell>overall</cell></row><row><cell cols="6">therapeutic efficacy. The data obtained for water</cell></row><row><cell cols="6">solubility is well correlated with that of Ali solubility</cell></row><row><cell cols="6">(Table 5). Plasma protein binding is a crucial factor in</cell></row><row><cell cols="6">drug discovery and development as it affects the</cell></row><row><cell cols="6">pharmacokinetics, distribution, and efficacy of a drug</cell></row><row><cell cols="6">in the body. Results show that most of the compounds</cell></row><row><cell cols="6">have remarkable plasma protein binding properties.</cell></row><row><cell cols="6">It is imperative to note that despite remarkable</cell></row><row><cell cols="6">pharmacokinetic profiles demonstrated by certain</cell></row><row><cell cols="6">compounds some few compounds also exhibit poor</cell></row><row><cell cols="6">pharmacokinetic profiles but are considered safe for</cell></row><row><cell cols="6">human use. Some compounds such as Bryophyllum</cell></row><row><cell cols="6">A, shows poor pharmacokinetic profile but is</cell></row><row><cell cols="6">considered safe for human use due while</cell></row><row><cell cols="6">Bryophyllum B show good pharmacokinetic profile</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgment</head><p>The authors thank the TETFUND IBR Grant for 2021/2022 financial support utilized for the present research.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Antibacterial activity of leaves and fruits extract of Tamarindus indica against clinical isolates of Escherichia coli and Shigella</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Abdallah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muhammad</surname></persName>
		</author>
		<idno type="DOI">10.15406/japlr.2018.07.00290</idno>
	</analytic>
	<monogr>
		<title level="j">J Anal Pharm Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="606" to="609" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Medicinal Uses of Cassia sieberiana ; A Review International Journal of Sciences : Medicinal Uses of Cassia sieberiana ; A Review</title>
		<author>
			<persName><forename type="first">M</forename><surname>Archer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Asafo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oteng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Atta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Journal of Sciences Basic and Applied Research (IJSBAR)</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="161" to="180" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Breast Cancer Treatments : Updates and New Challenges</title>
		<author>
			<persName><forename type="first">A</forename><surname>Burguin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Diorio</surname></persName>
		</author>
		<idno type="DOI">10.3390/jpm11080808</idno>
		<ptr target="https://doi.org/10.3390/jpm11080808" />
	</analytic>
	<monogr>
		<title level="j">J. Pers. Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">808</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">An in -silico method leads to recognition of hub genes and crucial pathways in survival of patients with breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dashti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Taheri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Fard</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-020-76024-2</idno>
		<ptr target="https://doi.org/10.1038/s41598-020-76024-2" />
	</analytic>
	<monogr>
		<title level="j">Scientific Reports</title>
		<imprint>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Carvacrol : An In Silico Approach of a Candidate Drug on HER2 , PI3K α , mTOR , hER-α , PR , and EGFR Receptors in the Breast Cancer</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">E</forename><surname>Faboro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Obafemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Farhat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Khemakhem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Michaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>; Calderon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yepes-P</forename><surname>Af</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Quinterosaumeth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Rojas-Armas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Palominopacheco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ortiz-S</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Peña-Rojas G</forename></persName>
		</author>
		<idno type="DOI">10.9734/EJMP/2016/26156</idno>
		<ptr target="https://doi.org/10.1155/2020/8830665" />
	</analytic>
	<monogr>
		<title level="j">Hindawi Evidence-Based Complementary and Alternative Medicine</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2016">2016. 2022. 2020</date>
		</imprint>
	</monogr>
	<note>European Journal of Medicinal Plants</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hussain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mashraqi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Khogeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Alzahrani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Anfinan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Alam</surname></persName>
		</author>
		<idno type="DOI">10.6026/97320630016882</idno>
		<ptr target="https://doi.org/10.6026/97320630016882" />
	</analytic>
	<monogr>
		<title level="j">Bioinformation</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="882" to="887" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications</title>
		<author>
			<persName><forename type="first">N</forename><surname>Iqbal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Iqbal</surname></persName>
		</author>
		<idno type="DOI">10.1155/2014/852748</idno>
		<ptr target="https://doi:10.1155/2014/852748" />
	</analytic>
	<monogr>
		<title level="j">Mol Biol Int</title>
		<imprint>
			<biblScope unit="page">852748</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Isolation and characterization of stigmasterol and β-sitosterol from Cassia sieberiana (Fabaceae) leaf extract</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">U</forename><surname>Odokpe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Chem Soc. Nigeri</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="135" to="142" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12957-021-02301-7</idno>
		<ptr target="https://doi.org/10.1186/s12957-021-02301-7" />
	</analytic>
	<monogr>
		<title level="j">World J. Surg. Onc</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">188</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Cassia tora Linn : A review on its ethnobotany, phytochemical and pharmacological profile</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Meena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename><surname>Niranjan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Pharmacy Research</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Design and Development of CARP -1 -NEMO Binding Inhibitors for Breast Cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Moo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sanford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Morrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sloan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cancer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cpet.2018.02.006</idno>
		<ptr target="https://doi.org/10.1016/j.cpet.2018.02.006" />
	</analytic>
	<monogr>
		<title level="j">HHS Public Access</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="339" to="354" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Determination of Antioxidant and α-Amylase Inhibition Properties of Alligator Pepper (Aframomum melegueta): A Potential Therapeutic Against Diabetes Mellitus</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Muhammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muhammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yunusa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Mikail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Dalhatu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">Y</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Sarki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Gwarzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Muhammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Mustapha</surname></persName>
		</author>
		<idno type="DOI">10.36349/easjpp.2022.v04i03.001</idno>
	</analytic>
	<monogr>
		<title level="j">EAS J. Pharm Pharmacol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="43" to="49" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Identification of potential SARS-CoV-2 papain-like protease inhibitors with the ability to interact with the catalytic triad</title>
		<author>
			<persName><forename type="first">M</forename><surname>Muhammad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">Y</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yunusa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Mikail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Alhassan</surname></persName>
		</author>
		<idno type="DOI">10.3934/biophy.2023005</idno>
		<ptr target="https://doi.org/10.3934/biophy.2023005" />
		<imprint>
			<date type="published" when="2022">2023. October 2022</date>
			<biblScope unit="page" from="50" to="66" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">In-silico molecular docking and pharmacokinetic studies of some selected phyto-constituents of Bryophyllum pinnatum as a potential selective inhibitor of monoamine oxidase-B (MAO-B)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ogidigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Anosike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fred</forename><forename type="middle">O</forename><surname>Nwodo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Omotuyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">I</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacologyonline</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="272" to="285" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Anticancer activity of Nigerian medicinal plants</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">O</forename><surname>Ohiagu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Chikezie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Chikezie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Enyoh</surname></persName>
		</author>
		<idno type="DOI">10.1186/s43094-021-00222-6</idno>
		<ptr target="https://doi.org/10.1186/s43094-021-00222-6" />
	</analytic>
	<monogr>
		<title level="j">Future Journal of Pharmaceutical Sciences</title>
		<imprint>
			<biblScope unit="page" from="2" to="21" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cassia tora Linn.: An Overview</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Pawar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D'mello</forename><surname>Pm</surname></persName>
		</author>
		<idno type="DOI">10.13040/IJPSR</idno>
		<ptr target="http://dx.doi.org/10.13040/IJPSR" />
	</analytic>
	<monogr>
		<title level="j">International Journal of Pharmaceutical Sciences and Research</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2286" to="2291" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptorpositive/HER2-positive breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pegram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jackisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Srd</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fahmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Syaban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Anoraga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Sabila</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41523-023-00533-2</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="2022">2023. 2023. 2022</date>
		</imprint>
	</monogr>
	<note>Molecular Docking Analysis from Bryophyllum Compound as A COVID-19</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Studies on the anti -asthmatic and antitussive properties of aqueous leaf extract of Bryophyllum pinnatum in rodent species</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">O</forename><surname>Salami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Ozolua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Okpo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Eze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Uwaya</surname></persName>
		</author>
		<idno type="DOI">10.3889/oamjms.2022.8412</idno>
		<ptr target="https://doi.org/10.1016/S1995-7645(13)60067-X" />
	</analytic>
	<monogr>
		<title level="j">Cytokine Storm. Therap Journal of Medical Sciences</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="421" to="425" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Asian Pacific Journal of Tropical Medicine</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Screening Docking and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Sarwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Girls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raipur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rudrapal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Debnath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bharat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Verma</surname></persName>
		</author>
		<idno type="DOI">10.9734/EJMP/2014/8549.SohrabSS.2022</idno>
		<ptr target="https://doi.org/10.3390/life12111729" />
	</analytic>
	<monogr>
		<title level="j">European Journal of Medicinal Plants</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">1729</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
	<note>Life</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Botanical aspects, phytochemicals, and toxicity of Tamarindus indica leaf and a systematic review of antioxidant capacities of T. indica leaf extracts</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sookying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Duangjai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saokaew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Phisalprapa</surname></persName>
		</author>
		<idno type="DOI">10.3389/fnut.2022.977015</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Nutr</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">977015</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Molecular Docking Approach of Bryophyllum pinnatum Compounds as Atherosclerosis Therapy By Targeting Adenosine Monophosphate-Activated Protein Kinase and Inducible Nitric Oxide Synthase</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">N</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.7150/ijbs.21635.YuniwatiY.2022</idno>
		<ptr target="https://doi.org/10.5455/aim.2022.30.91-95" />
	</analytic>
	<monogr>
		<title level="j">Int J Biol Sci</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="91" to="95" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Risk Factors and Preventions of Breast Cancer</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
